Oncolix (CE) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Oncolix Inc (CE) ONCX OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.000001 20:00:00
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
0.000001 0.000001 0.00 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.000001 USD

Oncolix (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.05k 2.05B 26.78M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
293.88k $ - - - -

more financials information »

Oncolix (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Oncolix (CE) Description

Oncolix is a clinical-stage biopharmaceutical company developing medical therapies for the treatment of cancer. Prolanta, covered by eight US and additional foreign patents, has two potential mechanisms of action - autophagy and prevention of chemoresistance. Our initial focus is the development, clinical testing and commercialization of Prolanta for the treatment of ovarian cancer. The FDA has provided clearance to commence a Phase 1 clinical trial of Prolanta in the treatment of ovarian cancer, which is now in progress. The FDA has granted Prolanta status as an Orphan Drug, providing potential tax benefits and market exclusivity. After completion of the Phase 1 study, we intend to conduct additional clinical trials in larger numbers of ovarian cancer patients to establish safety and efficacy. Oncolix will evaluate the use of Prolanta in combination with other chemotherapy drugs such as platinum-based drugs and taxanes. Prolanta has the potential to treat other cancers, including breast, endometrial and cervical. These studies may be performed in collaboration with larger pharmaceutical companies, either through licenses or joint ventures. Our scientific collaborators have demonstrated in animal models the efficacy of Prolanta in treating breast cancer, and we intend to engage academic collaborators to develop data for the treatment of other cancer types. Oncolix is also evaluating in-licensing or acquisition of other drug candidates, preferably in oncology.

Your Recent History
Oncolix (C..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.